29th week of 2011 patent applcation highlights part 44 |
Patent application number | Title | Published |
20110178036 | NOVEL SPINOSYN-PRODUCING POLYKETIDE SYNTHASES - The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in | 2011-07-21 |
20110178037 | HYDROPHOBICALLY ENHANCED AMINOGLYCOSIDES - Hydrophobically enhanced aminoglycosides have been prepared and shown to be effective antibacterial agents. These agents may be used in the treatment or prevention of various bacterial infections. Methods of preparing these agents also permit facile synthetic access. Formula (I). | 2011-07-21 |
20110178038 | Indole Antiviral Compositions And Methods - The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases. | 2011-07-21 |
20110178039 | OLIGOSACCHARIDE MIXTURES DERIVED FROM HEPARIN, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Oligosaccharide mixtures comprising anti-Xa activities of from 190 IU/mg to 450 IU/mg and anti-IIa activities of less than 0.2 IU/mg; and having constituent oligosaccharides with an average molecular weight of from 1800 to 2400 Daltons, constituent oligosaccharides comprise from 2 to 16 saccharide units, a 4,5-unsaturated uronic acid 2-O-sulfate unit at one end, and comprising at least one ΔIIa-IIs-Is hexasaccharide sequence are described. Processes for preparing the oligosaccharide mixtures, pharmaceutical compositions and articles of manufacture comprising the oligosaccharide mixtures are described. Methods of treatment and prevention comprising administering the oligosaccharide mixtures are described. | 2011-07-21 |
20110178040 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS - There is presently provided methods for delivering an anti-fibrotic or anti-cancer agent to a cell. The methods comprise contacting a cell with an effective amount of imidazolium and imidazolinium compounds as described herein, including imidazolium and imidazolinium salts. | 2011-07-21 |
20110178041 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT - Novel heterocyclic biaryl derivatives were disclosed which are useful as pharmaceutical agents and which exhibit a phosphodiesterase-inhibitory action. | 2011-07-21 |
20110178042 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents - The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II); and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B. L | 2011-07-21 |
20110178043 | Inhibitors of the mevalonate pathway of streptococcus pneumoniae - Compounds and related methods as can be used for selective mevalonate pathway inhibitors. | 2011-07-21 |
20110178044 | TRANSDERMAL ADMINISTRATION OF HYDROPHILIC DRUGS USING PERMEATION ENHANCER COMPOSITION - Methods, formulations, and drug delivery systems are provided for enhancing the flux of a transdermally administered hydrophilic drug using a basic permeation enhancer composition. The enhancer composition contains an inorganic hydroxide and a weaker, nitrogenous base, wherein the bases are selected such that a 0.1M aqueous solution of the nitrogenous base has a pH that is about 1.0 to about 6.5 lower than the pH of a 0.1M aqueous solution of the inorganic hydroxide. Additionally, the molar ratio of the nitrogenous base to the inorganic hydroxide in the enhancer composition is in the range of about 0.5n:1 to about 20n:1, where n is the number of hydroxide ions per molecule of the inorganic hydroxide. | 2011-07-21 |
20110178045 | Method to induce fatty liver in animal - The present invention discloses a method to induce fatty liver in an animal. The steps of the method comprise: feeding an animal with a high calorie diet, and injecting a mitochondrial inhibitor into the animal to inhibit the mitochondrial activity of the animal, then resulting in fat accumulation and inflammation in the liver of the animal. | 2011-07-21 |
20110178046 | Methods for Treating Glioblastoma - Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent. | 2011-07-21 |
20110178047 | Oxylipins From Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same - Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids. | 2011-07-21 |
20110178048 | STABILIZED FORMULATION OF TRIAMCINOLONE ACETONIDE - A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations. | 2011-07-21 |
20110178049 | AVERMECTIN/HYDROCORTISONE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN. E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and hydrocortisone or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 2011-07-21 |
20110178050 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF A HYPERACTIVE IMMUNE SYSTEM - There is disclosed use of certain picro derivatives of cyclolignans for prophylaxis or treatment of diseases or conditions characterised by a hyperactive immune system. Examples of cyclolignans according to the invention include picropodophyllin, deoxypicropodophyllin, anhydropicropodophyllol or deoxyanhydropicropodophyllol. Formula (I) | 2011-07-21 |
20110178051 | TOPICAL SKIN CARE COMPOSITION - A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma. | 2011-07-21 |
20110178052 | 9-ALPHA ESTRATRIENE DERIVATIVES AS ER-BETA SELECTIVE LIGANDS FOR THE PREVENTION AND TREATMENT OF INTESTINAL CANCER - Use of 9α-estra-1,3,5(10)-triene derivatives of formula (I) | 2011-07-21 |
20110178053 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME - The invention relates to novel azacarbonlines having formula (I), wherein: R3, R4 represent independently H; hal; CF | 2011-07-21 |
20110178054 | Heterocyclic GPCR Agonists - Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity. | 2011-07-21 |
20110178055 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS - The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula | 2011-07-21 |
20110178056 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS - Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated. | 2011-07-21 |
20110178057 | HETEROCYCLIC COMPOUND AND USE THEREOF - Compounds represented by the formulas (I) (II) wherein each symbol is as defined in the specification, and a pro-drug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like. | 2011-07-21 |
20110178058 | INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2011-07-21 |
20110178059 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS - Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B. | 2011-07-21 |
20110178060 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME - The present invention relates to a compound represented by the formula | 2011-07-21 |
20110178061 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS - Heterocyclic derivatives act as Ca channel antagonists. The compositions are useful for treating or relieving Ca channel mediated conditions. | 2011-07-21 |
20110178062 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR - Certain substituted indole and benzothiophene compounds are histamine H | 2011-07-21 |
20110178063 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES - The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity. | 2011-07-21 |
20110178064 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL - In one aspect, the present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to method for their preparation. | 2011-07-21 |
20110178065 | NOVEL CYP17 INHIBITORS - Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions. | 2011-07-21 |
20110178066 | Hydroxypiperidine derivatives and uses thereof - Chemical agents, such as derivatives of hydroxypiperidine moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents. | 2011-07-21 |
20110178067 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following: | 2011-07-21 |
20110178068 | Quaternary Ammonium Salt Prodrugs - The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X | 2011-07-21 |
20110178069 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME - The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds. | 2011-07-21 |
20110178070 | PI3K/mTOR INHIBITORS - The invention relates to PI3K/mTOR inhibiting compounds consisting of the formula: | 2011-07-21 |
20110178071 | Antiviral Treatments - Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C. | 2011-07-21 |
20110178072 | STEREOSPECIFICITY OF METHYLSULFINYL REDUCTION - This disclosure relates to compositions and methods of use involving compounds (e.g., drugs) containing methylsulfinyl moieties. For example, a compound may be administered in an excess of either the R- or S-epimer of the methylsulfinyl moiety based on whether the compound exhibits higher biological activity when the methylsulfinyl moiety is present in the methylsulfinyl-oxidized form or the methylsulfide-reduced form. | 2011-07-21 |
20110178073 | METHODS OF IMPROVING COGNITIVE FUNCTIONS - Methods and articles of manufacture for use in improving a cognitive function, utilizing a conjugate comprising a first moiety having GABA agonist activity and a second moiety having CNS activity being covalently linked to the first moiety, are disclosed. Also disclosed are methods and articles of manufacture of preventing onset or inhibiting progression of a cognitive impairment or dysfunction utilizing the disclosed conjugate. | 2011-07-21 |
20110178074 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS - The present invention is related to methods of treating bacterial infections in mammals using antipathogenic benzamide compounds having the formula | 2011-07-21 |
20110178075 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF - The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. | 2011-07-21 |
20110178076 | MEDICAL INTERVENTION IN HAEMATOLOGICAL CANCERS - The present invention relates to the medical and pharmaceutical use of substituted 1H-imidazo[4,5-c]quinolin-4-amines, in particular Imiquimod® and Gardiquimod®, alone or preferably in combination with Akt inhibitors, in particular with Akti1/2 and AktX, and most preferably with Akti1/2, in the treatment, prevention and/or amelioration of haematological cancers, in particular multiple myeloma disorders or B-cell disorders, and most particular in the therapy of multiple myeloma. | 2011-07-21 |
20110178077 | Anti-infective compounds - The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis. | 2011-07-21 |
20110178078 | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF - The invention relates to the novel substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines of the general formula 1, pharmaceutically acceptable salts and/or hydrates thereof, serotonin 5-HT | 2011-07-21 |
20110178079 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS - Novel guanidine compounds having the formula | 2011-07-21 |
20110178080 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds - Melanocortin receptor-specific compounds of formula I below: | 2011-07-21 |
20110178081 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). | 2011-07-21 |
20110178082 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). | 2011-07-21 |
20110178083 | PDE-10 INHIBITORS - Vicinal substituted cyclopropyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function, for example neurological, neurodegenerative and psychiatric disorders including, but not limited to, those comprising cognitive deficits or schizophrenic symptoms. | 2011-07-21 |
20110178084 | THERAPEUTIC COMPOUNDS - Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed, wherein a dashed line represents the presence or absence of a bond; and, wherein Y, A, R, D, and n are as described. Methods, compositions, and medicaments related thereto are also disclosed. | 2011-07-21 |
20110178085 | Salts of N-[6-cis-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(t- rifluoromethoxy)[1,1'-biphenyl]-3-carboxamide - Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide are prepared and characterized. | 2011-07-21 |
20110178086 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME - The present invention provides adamantyl-diamide derivatives of formula (I): | 2011-07-21 |
20110178087 | Compositions and Their Use as Anti-Tumor Agents - The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas. | 2011-07-21 |
20110178088 | TETRAHYDRO-NAPHTHALENE DERIVATIVES - This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. | 2011-07-21 |
20110178089 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS - This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula | 2011-07-21 |
20110178090 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF - Compounds of Formula (I): | 2011-07-21 |
20110178091 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS - The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders. | 2011-07-21 |
20110178092 | HIV-1 Protease Inhibitors - Described are novel protease inhibitors and methods for using said protease inhibitors in the treatment of human immunodeficiency virus (HIV) infection. | 2011-07-21 |
20110178093 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer. | 2011-07-21 |
20110178094 | Oral Formulation - The invention relates to a pharmaceutical composition intended for oral administration comprising low doses of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and to a composition comprising the compound. | 2011-07-21 |
20110178095 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors. | 2011-07-21 |
20110178096 | OCTAHYDROPENTALENE COMPOUNDS AS CHEMOKINE RECEPTOR ANTAGONISTS - The present invention is directed to novel compounds of Formula (I) | 2011-07-21 |
20110178097 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-Q- UINOLIN-2-ONE LACTIC ACID SALTS - The present invention relates to non-hydrate crystalline forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts. | 2011-07-21 |
20110178098 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME - In one aspect, the invention relates to compounds having anticancer activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2011-07-21 |
20110178099 | Pharmaceutical combination - The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 2011-07-21 |
20110178100 | APOPTOSIS INHIBITOR - It is directed to provide a novel apoptosis inhibitor. Specifically directed is an apoptosis inhibitor containing a biphenylcarboxamide compound represented by the following formula (1) as an active ingredient, wherein R | 2011-07-21 |
20110178101 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS - In one aspect, the invention relates to compounds having the formula: | 2011-07-21 |
20110178102 | SIR2 REGULATION - Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed. | 2011-07-21 |
20110178103 | THERAPEUTIC AGENT FOR CHRONIC RENAL FAILURE - The present invention aims to provide a therapeutic agent for chronic renal failure, comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof. That is, the present invention provides provision of a drug comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof, which drug is useful not only for amelioration of renal function, but also for amelioration of anemia, activation of SOD and excretion of uremic substances. | 2011-07-21 |
20110178104 | Anti-Heparin Compounds - The present invention provides compounds and methods for antagonizing the anticoagulant effect of an anticoagulant agent that is selected from UFH, LMWH, and a heparin/LMWH derivative in a patient comprising administering to the patient a compound of the invention or a salt thereof, or a composition comprising the same. | 2011-07-21 |
20110178105 | CLINICAL BENEFITS OF EICOSAPENTAENOIC ACID IN HUMANS - Methods are provided for maintaining or lowering lipoprotein-associated phospholipase A | 2011-07-21 |
20110178106 | 5-QUINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND USE THEREOF - 5-Quinolinone and Imidazopyrimidine compounds are provided that are useful for inhibiting the efflux of any therapeutic agent that is a MRP1 substrate. Also provided is a method for screening to identify additional MRP1 inhibitors. | 2011-07-21 |
20110178107 | HCV PROTEASE INHIBITORS - This invention relates to compounds of Formula (I), (II), or (III) shown in the specification. These compounds can be used to treat hepatitis C virus infection. | 2011-07-21 |
20110178108 | Group of amino substituted benzoyl derivatives and their preparation and their use - A group of amino substituted benzoyl derivatives, their preparation and their use. The screening and research on an antiviral drug with hA3G/Vif as a target point proves that the 3-amino benzoyl derivatives not only have the combined activity for the hA3G/Vif, but also have a function of inhibiting replication of viruses. The present invention provides the possible breakthrough progress for the problem of HIV drug resistance, thereby providing a novel clinical antiviral drug which has higher efficiency. | 2011-07-21 |
20110178109 | PEST CONTROL COMPOSITION AND PEST CONTROL METHOD - A pest controlling composition comprising, as active ingredients, a pyrimidine compound represented by Formula (1): | 2011-07-21 |
20110178110 | Genotype and Expression Analysis for Use in Predicting Outcome and Therapy Selection - The invention provides compositions and methods for determining the likelihood of successful treatment with a various treatment regimens available to gastrointestinal cancer patients. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating these patients. | 2011-07-21 |
20110178111 | LONG-TERM TREATMENT OF SYMPTOMATIC HEART FAILURE - The main object here is the use of omega-3 polyunsaturated fatty acids (as ethyl esters, hereinafter called “n-3 PUFA”) as a medicament, either alone or in combination with other therapeutic agents, for reducing mortality for a cardiovascular cause, in particular arrhythmia or for reducing hospitalization for any cause, in particular a cardiovascular cause and for the daily administration to patients with symptomatic heart failure (HF) for more than 3.5 years. | 2011-07-21 |
20110178112 | PPAR Modulators - 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections. | 2011-07-21 |
20110178113 | METHODS OF TREATING TRAVELER'S DIARRHEA AND HEPATIC ENCEPHALOPATHY - Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin. | 2011-07-21 |
20110178114 | TOPICAL REGIONAL NEURO-AFFECTIVE THERAPY - A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed. | 2011-07-21 |
20110178115 | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS - Compounds of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma. | 2011-07-21 |
20110178116 | Methods of stimulating immune response in certain individuals - The present invention is directed to a method of increasing the time period between outbreaks of genital herpes comprising providing an imidazoquinolinamine formulation, disposing an amount of the imidazoquinolinamine formulation into a first nare of an individual infected with Herpes Simplex Virus type 2, covering at least a portion of the internal surface of the individual's first nare with a portion of the amount of the imidazoquinolinamine in the nare, massaging the portion of the amount of the imidazoquinolinamine into the internal surface of the first nare, disposing the amount of the imidazoquinolinamine formulation into a second nare of the individual, covering at least a portion of the internal surface of the second nare with a portion of the amount of the imidazoquinolinamine in said nare and massaging the portion of the amount of the imidazoquinolinamine into the internal surface of said nare. | 2011-07-21 |
20110178117 | OXAZOLOBENZIMIDAZOLE DERIVATIVES - The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 2011-07-21 |
20110178118 | PALONOSETRON FOR THE TREATMENT OF CHEMOTHERAPY INDUCED EMESES - Methods and compositions for reducing chemotherapy and radiotherapy induced emises with 5-HT | 2011-07-21 |
20110178119 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase - The invention provides N-bicyclic sulfonamido compounds of Formula (I) wherein A is as described in the specification and R | 2011-07-21 |
20110178120 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE - The present invention relates to pyridoxine (vitamin B | 2011-07-21 |
20110178121 | Methods for Treating Pain - The present invention is directed to methods of treating pain by administering a therapeutically effective amount of an α7 nAChR ligand or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment thereof and to pharmaceutical compositions comprising such a compound or salt. | 2011-07-21 |
20110178122 | Quinolizidinone M1 Receptor Positive Allosteric Modulators - The present invention is directed to quinolizidinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 2011-07-21 |
20110178123 | NONPEPTIDE HIV-1 PROTEASE INHIBITORS - Novel compounds and compositions for treating patients in need of relief from HIV, AIDS, and AIDS-related diseases are described. Methods for treating HIV, AIDS, and AIDS-related diseases using the compounds described herein are also described. | 2011-07-21 |
20110178124 | PYRIDINIUM AND QUINOLINIUM DERIVATIVES - The invention provides compounds of formula I blocking phosphorylcholine biosynthesis by means of the selective blocking of the choline kinase enzyme in tumor cells or in cells affected by parasitic infection and therefore being applicable in the treatment of tumors and parasitic diseases or diseases produced by viruses and fungi in animals, including human beings; as well as to a method for preparing the compounds of the invention and certain intermediates of said method. | 2011-07-21 |
20110178125 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS - This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. | 2011-07-21 |
20110178126 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS - Pharmaceutical compositions and compounds are provided. The compounds of the invention have use as therapeutic agents, e.g., they demonstrate anti-proliferative, anti-inflammatory, anti-angiogenic, anti-migration activities. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of, e.g., anti-inflammatory, renal, and hyperproliferative disorders. The compounds of the invention are pyrazolylbenzothiazole derivatives of the following formula (1) | 2011-07-21 |
20110178127 | AMINE COMPOUNDS AND MEDICAL USES THEREOF - The present invention relates to a new amine compound or a pharmaceutically acceptable salt thereof, wherein the definitions of X, R | 2011-07-21 |
20110178128 | BENZIMIDAZOLE COMPOUND IN CRYSTAL FORM AND SALT THEREOF - The present invention aims to provide a stable form of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, which is free of problems of water adsorption and the like, and shows superior water solubility. | 2011-07-21 |
20110178129 | INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2011-07-21 |
20110178130 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa - The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes. | 2011-07-21 |
20110178131 | Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine - Compounds of formula (I) or a salt thereof are provided: | 2011-07-21 |
20110178132 | PYRIDINE COMPOUND AND USE THEREOF FOR PEST CONTROL - Disclosed is a pyridine compound represented by general formula (I). | 2011-07-21 |
20110178133 | CALCIUM RECEPTOR MODULATING AGENTS - The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I. | 2011-07-21 |
20110178134 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof - The invention relates to compounds of formula (I) wherein the groups have stated meanings, and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome. | 2011-07-21 |
20110178135 | SALTS AND CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR - The present invention provides salts and crystalline forms of the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide, and pharmaceutical compositions and method of use thereof. | 2011-07-21 |